Intrinsic value of CryoPort - CYRX

Previous Close

$10.30

  Intrinsic Value

$5.23

stock screener

  Rating & Target

sell

-49%

Previous close

$10.30

 
Intrinsic value

$5.23

 
Up/down potential

-49%

 
Rating

sell

We calculate the intrinsic value of CYRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  58.60
  53.24
  48.42
  44.07
  40.17
  36.65
  33.49
  30.64
  28.07
  25.77
  23.69
  21.82
  20.14
  18.62
  17.26
  16.04
  14.93
  13.94
  13.05
  12.24
  11.52
  10.86
  10.28
  9.75
  9.28
  8.85
  8.46
  8.12
  7.81
  7.52
Revenue, $m
  19
  29
  43
  62
  87
  119
  159
  208
  266
  334
  413
  504
  605
  718
  842
  977
  1,122
  1,279
  1,446
  1,623
  1,809
  2,006
  2,212
  2,428
  2,653
  2,888
  3,132
  3,387
  3,651
  3,926
Variable operating expenses, $m
  16
  24
  36
  52
  72
  99
  132
  173
  221
  278
  344
  419
  504
  597
  700
  813
  934
  1,064
  1,203
  1,350
  1,506
  1,670
  1,841
  2,021
  2,208
  2,403
  2,607
  2,818
  3,038
  3,267
Fixed operating expenses, $m
  10
  10
  11
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  14
  14
  14
  14
  15
  15
  15
  16
  16
  16
  17
  17
  18
  18
  18
  19
  19
Total operating expenses, $m
  26
  34
  47
  63
  83
  110
  144
  185
  233
  290
  357
  432
  517
  611
  714
  827
  948
  1,079
  1,218
  1,365
  1,522
  1,686
  1,857
  2,038
  2,225
  2,421
  2,625
  2,836
  3,057
  3,286
Operating income, $m
  -7
  -6
  -3
  0
  3
  9
  15
  23
  32
  44
  57
  72
  88
  107
  127
  150
  174
  200
  227
  257
  288
  320
  355
  390
  428
  467
  507
  550
  594
  639
EBITDA, $m
  -6
  -5
  -2
  2
  6
  12
  20
  30
  41
  54
  70
  88
  108
  130
  155
  181
  210
  241
  274
  309
  346
  385
  426
  469
  514
  560
  609
  659
  712
  767
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  2
  2
  3
  3
  4
  5
  6
  8
  9
  10
  12
  14
  15
  17
  19
  21
  24
  26
  28
  31
  33
  36
  39
Earnings before tax, $m
  -7
  -6
  -4
  -1
  3
  8
  14
  21
  30
  41
  53
  67
  83
  100
  120
  141
  163
  188
  214
  241
  271
  301
  333
  367
  402
  439
  477
  516
  558
  600
Tax expense, $m
  0
  0
  0
  0
  1
  2
  4
  6
  8
  11
  14
  18
  22
  27
  32
  38
  44
  51
  58
  65
  73
  81
  90
  99
  109
  118
  129
  139
  151
  162
Net income, $m
  -7
  -6
  -4
  -1
  2
  6
  10
  16
  22
  30
  39
  49
  61
  73
  87
  103
  119
  137
  156
  176
  197
  220
  243
  268
  293
  320
  348
  377
  407
  438

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  11
  17
  25
  36
  51
  70
  93
  122
  156
  196
  243
  296
  355
  421
  494
  573
  659
  750
  848
  952
  1,062
  1,177
  1,298
  1,425
  1,557
  1,695
  1,838
  1,987
  2,143
  2,304
Adjusted assets (=assets-cash), $m
  11
  17
  25
  36
  51
  70
  93
  122
  156
  196
  243
  296
  355
  421
  494
  573
  659
  750
  848
  952
  1,062
  1,177
  1,298
  1,425
  1,557
  1,695
  1,838
  1,987
  2,143
  2,304
Revenue / Adjusted assets
  1.727
  1.706
  1.720
  1.722
  1.706
  1.700
  1.710
  1.705
  1.705
  1.704
  1.700
  1.703
  1.704
  1.705
  1.704
  1.705
  1.703
  1.705
  1.705
  1.705
  1.703
  1.704
  1.704
  1.704
  1.704
  1.704
  1.704
  1.705
  1.704
  1.704
Average production assets, $m
  3
  5
  7
  10
  14
  19
  26
  34
  43
  54
  67
  82
  98
  116
  136
  158
  182
  207
  234
  263
  293
  325
  358
  393
  430
  468
  507
  549
  591
  636
Working capital, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -12
  -15
  -17
  -20
  -23
  -27
  -31
  -35
  -39
  -43
  -48
  -53
  -58
  -64
  -69
  -75
  -81
  -88
  -94
Total debt, $m
  1
  3
  6
  10
  15
  21
  29
  39
  50
  64
  80
  98
  118
  140
  165
  191
  220
  251
  284
  319
  357
  396
  436
  479
  524
  570
  619
  669
  722
  776
Total liabilities, $m
  4
  6
  9
  12
  17
  24
  32
  41
  53
  66
  82
  100
  120
  142
  167
  194
  223
  254
  287
  322
  359
  398
  439
  482
  526
  573
  621
  672
  724
  779
Total equity, $m
  7
  11
  17
  24
  34
  46
  62
  81
  103
  130
  161
  196
  235
  279
  327
  379
  436
  497
  562
  630
  703
  779
  859
  943
  1,031
  1,122
  1,217
  1,316
  1,418
  1,525
Total liabilities and equity, $m
  11
  17
  26
  36
  51
  70
  94
  122
  156
  196
  243
  296
  355
  421
  494
  573
  659
  751
  849
  952
  1,062
  1,177
  1,298
  1,425
  1,557
  1,695
  1,838
  1,988
  2,142
  2,304
Debt-to-equity ratio
  0.190
  0.300
  0.370
  0.410
  0.440
  0.460
  0.470
  0.480
  0.490
  0.490
  0.500
  0.500
  0.500
  0.500
  0.500
  0.500
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
Adjusted equity ratio
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -7
  -6
  -4
  -1
  2
  6
  10
  16
  22
  30
  39
  49
  61
  73
  87
  103
  119
  137
  156
  176
  197
  220
  243
  268
  293
  320
  348
  377
  407
  438
Depreciation, amort., depletion, $m
  1
  1
  1
  2
  3
  4
  5
  7
  9
  11
  13
  16
  20
  23
  27
  32
  36
  41
  47
  53
  59
  65
  72
  79
  86
  94
  101
  110
  118
  127
Funds from operations, $m
  -6
  -5
  -2
  1
  5
  10
  15
  22
  31
  41
  52
  65
  80
  97
  115
  134
  156
  179
  203
  229
  256
  285
  315
  346
  379
  414
  449
  487
  525
  565
Change in working capital, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
Cash from operations, $m
  -6
  -4
  -2
  2
  6
  10
  16
  23
  32
  42
  54
  68
  83
  99
  118
  138
  159
  182
  207
  233
  261
  290
  320
  352
  385
  419
  455
  493
  532
  572
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -16
  -20
  -23
  -27
  -32
  -36
  -41
  -47
  -53
  -59
  -65
  -72
  -79
  -86
  -94
  -101
  -110
  -118
New CAPEX, $m
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -8
  -9
  -11
  -13
  -15
  -16
  -18
  -20
  -22
  -24
  -25
  -27
  -29
  -30
  -32
  -33
  -35
  -36
  -38
  -40
  -41
  -43
  -45
Cash from investing activities, $m
  -1
  -3
  -3
  -4
  -6
  -8
  -10
  -13
  -16
  -20
  -24
  -28
  -32
  -38
  -43
  -49
  -56
  -61
  -68
  -76
  -83
  -91
  -98
  -107
  -115
  -124
  -134
  -142
  -153
  -163
Free cash flow, $m
  -8
  -7
  -5
  -3
  0
  2
  6
  10
  16
  23
  30
  40
  50
  61
  74
  89
  104
  121
  138
  158
  178
  199
  222
  245
  270
  295
  322
  350
  379
  409
Issuance/(repayment) of debt, $m
  1
  2
  3
  4
  5
  6
  8
  10
  12
  14
  16
  18
  20
  22
  25
  27
  29
  31
  33
  35
  37
  39
  41
  43
  45
  47
  48
  50
  52
  54
Issuance/(repurchase) of shares, $m
  10
  10
  9
  8
  8
  7
  5
  3
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  11
  12
  12
  12
  13
  13
  13
  13
  13
  14
  16
  18
  20
  22
  25
  27
  29
  31
  33
  35
  37
  39
  41
  43
  45
  47
  48
  50
  52
  54
Total cash flow (excl. dividends), $m
  4
  5
  7
  9
  12
  15
  19
  23
  28
  36
  46
  57
  70
  84
  99
  115
  133
  152
  172
  193
  215
  238
  262
  288
  314
  342
  371
  400
  432
  464
Retained Cash Flow (-), $m
  -10
  -10
  -9
  -8
  -10
  -12
  -15
  -19
  -23
  -27
  -31
  -35
  -39
  -44
  -48
  -52
  -57
  -61
  -65
  -69
  -73
  -76
  -80
  -84
  -87
  -91
  -95
  -99
  -103
  -107
Prev. year cash balance distribution, $m
  13
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  7
  -5
  -2
  1
  2
  3
  4
  5
  5
  10
  15
  22
  31
  40
  51
  63
  76
  91
  107
  124
  142
  162
  182
  204
  227
  251
  276
  302
  329
  357
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  7
  -4
  -2
  1
  2
  2
  3
  3
  3
  5
  7
  10
  12
  13
  15
  16
  17
  17
  16
  16
  15
  13
  12
  10
  9
  7
  6
  5
  4
  3
Current shareholders' claim on cash, %
  82.7
  73.2
  67.7
  64.6
  62.6
  61.4
  60.7
  60.4
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3
  60.3

Cryoport, Inc. (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients. The Company's Cryoport Express Solution includes a cloud-based logistics operating platform, which is branded as the Cryoportal. The Company's Cryoport Express Solutions are made up of the Cryoportal software platform, Cryoport Express Shippers, Cryoport Express Smart Pak data loggers and its life sciences cold chain logistics expertise. The Cryoportal is used by the Company, its clients and its business partners to automate the entry of orders, prepare customs documentation, and to facilitate status and location monitoring of shipped orders while in transit.

FINANCIAL RATIOS  of  CryoPort (CYRX)

Valuation Ratios
P/E Ratio -18.1
Price to Sales 30.2
Price to Book 30.2
Price to Tangible Book
Price to Cash Flow -45.3
Price to Free Cash Flow -36.3
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 5
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 16.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -142.9%
Ret/ On Assets - 3 Yr. Avg. -215%
Return On Total Capital -181.8%
Ret/ On T. Cap. - 3 Yr. Avg. -327.3%
Return On Equity -222.2%
Return On Equity - 3 Yr. Avg. -63%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 50%
Gross Margin - 3 Yr. Avg. 36.1%
EBITDA Margin -166.7%
EBITDA Margin - 3 Yr. Avg. -169.4%
Operating Margin -100%
Oper. Margin - 3 Yr. Avg. -133.3%
Pre-Tax Margin -166.7%
Pre-Tax Margin - 3 Yr. Avg. -169.4%
Net Profit Margin -166.7%
Net Profit Margin - 3 Yr. Avg. -169.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CYRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CYRX stock intrinsic value calculation we used $11.954267 million for the last fiscal year's total revenue generated by CryoPort. The default revenue input number comes from 0001 income statement of CryoPort. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CYRX stock valuation model: a) initial revenue growth rate of 58.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CYRX is calculated based on our internal credit rating of CryoPort, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CryoPort.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CYRX stock the variable cost ratio is equal to 83.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $10 million in the base year in the intrinsic value calculation for CYRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for CryoPort.

Corporate tax rate of 27% is the nominal tax rate for CryoPort. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CYRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CYRX are equal to 16.2%.

Life of production assets of 3 years is the average useful life of capital assets used in CryoPort operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CYRX is equal to -2.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $17.886766 million for CryoPort - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 28.57 million for CryoPort is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CryoPort at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
GEF Greif Cl A 50.73 141.29  str.buy
TRS TriMas 30.14 0.17  str.sell
GFN General Financ 14.30 4.83  str.sell
WAIR Wesco Aircraft 11.26 9.64  sell

COMPANY NEWS

▶ Los Angeles stocks that are driving Wall Street's latest bull run   [Aug-23-18 02:31PM  American City Business Journals]
▶ When Should You Buy Cryoport Inc (NASDAQ:CYRX)?   [Jun-27-18 08:35AM  Simply Wall St.]
▶ CryoPort, Inc. to Host Earnings Call   [12:15PM  ACCESSWIRE]
▶ ETFs with exposure to CryoPort, Inc. : December 28, 2017   [Dec-28-17 12:01PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : December 5, 2017   [Dec-05-17 12:37PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : November 24, 2017   [Nov-24-17 10:33AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : November 13, 2017   [Nov-13-17 12:10PM  Capital Cube]
▶ CYRX: Record Revenue, Again. Readying To Support Immunotherapy Launches   [Nov-07-17 04:00PM  Zacks Small Cap Research]
▶ Cryoport Revenue Up 52%; Driven by BioPharma   [Nov-02-17 04:10PM  PR Newswire]
▶ Cryoport, Inc. to Host Earnings Call   [11:40AM  ACCESSWIRE]
▶ Is It Too Late To Buy Cryoport Inc (CYRX)?   [07:02AM  Simply Wall St.]
▶ ETFs with exposure to CryoPort, Inc. : November 1, 2017   [Nov-01-17 12:04PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : October 16, 2017   [Oct-16-17 09:50AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : October 2, 2017   [Oct-02-17 10:47AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : September 19, 2017   [Sep-19-17 05:20PM  Capital Cube]
▶ CYRX: Raising Price Target on CAR-T Opportunity   [Aug-16-17 10:00AM  Zacks Small Cap Research]
▶ Cryoport Launches - Cryoport. Certified. Cool.   [Aug-15-17 08:45AM  PR Newswire]
▶ ETFs with exposure to CryoPort, Inc. : August 4, 2017   [Aug-03-17 08:10PM  Capital Cube]
▶ FDA Panel Votes To Approve CTL019, Positive Implications for CYRX   [Jul-19-17 01:30PM  Zacks Small Cap Research]
▶ CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter   [May-09-17 03:40PM  Zacks Small Cap Research]
▶ Cryoport Revenue Grows by 74%, Driven by Biopharma   [May-04-17 04:10PM  PR Newswire]
▶ CYRX: Growth in Clinical Trial Customers Pushing Revenue To Record Heights   [Mar-20-17 09:00AM  Zacks Small Cap Research]
▶ Webcast-Q4 Earnings Call for CryoPort, Inc.   [Mar-07-17 11:11PM  at Company Spotlight]
▶ Cryoport Completes Warrant Tender Offer   [08:30AM  PR Newswire]
▶ Cryoport Supporting Over 100 Clinical Trials   [Oct-25-16 08:30AM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.